Healthcare & Life Sciences
Target Company
Cyprotex PLC (AIM:CRX)
Evotec AG (XTRA:EVT)

Client Description:

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry, and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010, and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics, and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target-based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology, and high content toxicology screening services, including its proprietary CellCiphr(R) toxicity prediction technology, bioscience services, and predictive modeling solutions including Cloe(R) PK, chemPK(TM), chemTarget, chemTox, and DDI-Fusion and a range of skin, ocular, and endocrine disruption services. For more information, please visit